Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced the publication of a feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.” The piece underscores the limitations of legacy systems and details how the Company’s flagship IzoView Breast CT Imaging System was purpose-built for AI-driven imaging. Key points include global validation of AI’s role in improving cancer detection, IzoView’s proprietary 3D hardware and 10-second compression-free scans, and its positioning as a scalable, protected platform with a $500,000 target price designed to set a new standard in breast cancer screening.
To view the full press release, visit https://ibn.fm/wMHpB
About Izotropic
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
HeartBeam (NASDAQ: BEAT) is positioned amid limitations of traditional 12-lead electrocardiogram (“ECG”) systems, often including cumbersome…
Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical-stage biopharmaceutical company leveraging its RADR AI platform to…
Clene (NASDAQ: CLNN) announced presentation of combined REPAIR-MS trial results at the 41st Congress of…
Nutriband (NASDAQ: NTRB) announced it will participate in the MicroCap Rodeo Conference in New York…
Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug…